GHRP-2

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide that stimulates the release of growth hormone (GH) from the anterior pituitary gland. Developed in the early 1990s, it acts as an agonist at the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHS-R1a), mimicking the action of the endogenous gut hormone ghrelin. GHRP-2 was one of the first synthetic GH secretagogues developed and remains widely used in research settings for studying GH axis physiology.

Mechanism of Action

GHRP-2 exerts its GH-releasing effects through activation of the ghrelin receptor (GHS-R1a) on somatotroph cells in the anterior pituitary. This receptor is a G-protein coupled receptor that, when activated, stimulates intracellular calcium mobilization and activates protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling pathways, leading to GH gene transcription and secretion.

The compound's action is complementary to, and synergistic with, growth hormone-releasing hormone (GHRH). While GHRH acts through its own receptor (GHRHR) to stimulate GH release, GHRP-2 activates a distinct receptor pathway. When administered together, GHRP-2 and GHRH produce GH responses that are greater than the sum of their individual effects, demonstrating true pharmacological synergy at the pituitary level.

Beyond GH release, GHRP-2 also stimulates the release of adrenocorticotropic hormone (ACTH) and cortisol from the pituitary and adrenal glands, respectively. This is thought to occur through direct action on corticotroph cells, as GHS-R1a receptors are expressed on ACTH-producing cells in addition to somatotrophs. The cortisol-elevating effect is dose-dependent and represents one of the compound's key pharmacological distinctions from more selective secretagogues like ipamorelin.

GHRP-2 also causes moderate elevation of prolactin levels, likely through direct action on lactotroph cells. The magnitude of prolactin elevation is generally less than that observed with GHRP-6 but greater than with ipamorelin. Additionally, GHRP-2 has been shown to stimulate appetite through hypothalamic ghrelin receptor activation, though this effect is less pronounced than with GHRP-6.

Pharmacokinetics

GHRP-2 has been characterized in both animal and human studies. In human pharmacokinetic studies, the compound demonstrates rapid absorption following subcutaneous injection, with peak plasma concentrations achieved within 15–30 minutes. The distribution half-life is approximately 7–10 minutes, and the elimination half-life is approximately 40–60 minutes, resulting in a total duration of GH-elevating activity of approximately 2–3 hours per dose.

The compound shows a dose-dependent GH response, with doses of 100–300 mcg producing significant GH elevations in healthy subjects. The GH response to GHRP-2 is pulsatile and mirrors the natural pattern of GH secretion, though the magnitude of individual pulses can be substantially greater than endogenous peaks. Repeated dosing at 12-hour intervals maintains elevated GH levels without significant receptor desensitization over periods of several weeks.

GHRP-2 is administered subcutaneously in research settings. The compound is also active via intranasal and oral routes, though bioavailability is reduced compared to parenteral administration. The peptide is subject to hepatic and renal clearance, with the intact peptide appearing in urine in small quantities.

The cortisol and prolactin elevations follow a similar time course to GH release, peaking within 30–60 minutes and returning to baseline within 2–3 hours. The magnitude of cortisol elevation is typically 2–3 times baseline values at standard research doses, while prolactin elevations are generally 1.5–2 times baseline.

Clinical Evidence

GHRP-2 has been studied in multiple human clinical trials, primarily as a diagnostic tool for GH deficiency and as a research compound for understanding GH axis physiology. Key published studies include:

• Bowers et al. (1990): Initial characterization of GHRP-2's GH-releasing activity in humans, demonstrating potent, dose-dependent GH stimulation.
• Puche et al. (1992): Pharmacokinetic and pharmacodynamic characterization in healthy volunteers, establishing the compound's rapid onset and short duration of action.
• Arvat et al. (1995): Comparative study showing GHRP-2's synergistic effects with GHRH and its differential effects on ACTH and cortisol compared to GHRH alone.
• Popovic et al. (2003): Evaluation of GHRP-2 as a diagnostic provocative test for GH deficiency, demonstrating high sensitivity and specificity.

The compound has been used extensively as a research tool for studying GH axis regulation, including investigations into aging-related GH decline, the effects of nutritional status on GH secretion, and the interaction between GH and other neuroendocrine axes. However, GHRP-2 has not been developed as a therapeutic agent, and no pharmaceutical product containing GHRP-2 has received regulatory approval.

The evidence grade of C reflects the existence of controlled human pharmacokinetic and pharmacodynamic data, but the absence of efficacy trials for any clinical indication. The compound is well-characterized pharmacologically but lacks the clinical development data that would support therapeutic claims.

Community Experiences

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"GHRP-2 gave me noticeably better sleep quality and recovery between training sessions. The hunger increase was manageable — not as intense as GHRP-6 — and I could work around it with meal timing." — r/Peptides user (reported using 200 mcg twice daily for 8 weeks)

"My IGF-1 levels increased significantly on bloodwork after 6 weeks of GHRP-2. The recovery from heavy training sessions improved, and I noticed better skin quality and joint comfort." — r/Biohackers user (reported IGF-1 increase from 180 to 280 ng/mL)

"The appetite stimulation was actually helpful for me — I struggle to eat enough during bulking phases. GHRP-2 made it easier to hit my calorie targets while supporting recovery." — r/Peptides user (reported using alongside caloric surplus)

Frequently Asked Questions

How does GHRP-2 differ from GHRP-6? GHRP-2 causes less appetite stimulation than GHRP-6 but produces greater cortisol and prolactin elevation. GHRP-6 has a slightly longer duration of action. Both compounds act on the ghrelin receptor, but their secondary pharmacological profiles differ meaningfully.

Does GHRP-2 increase cortisol significantly? Yes. GHRP-2 causes dose-dependent cortisol elevation, typically 2–3 times baseline at standard research doses. This is a pharmacological effect, not a stress response, and occurs through direct action on corticotroph cells. The clinical significance of this elevation in research use is not fully established.

What is the difference between GHRP-2 and ipamorelin? Ipamorelin is a more selective GH secretagogue that produces GH release with minimal effects on cortisol, prolactin, or appetite. GHRP-2 has a broader pharmacological profile with more pronounced effects on ACTH, cortisol, and prolactin. Ipamorelin is generally preferred for applications where selective GH stimulation is desired.

How often should GHRP-2 be dosed? Research protocols typically use 100–300 mcg administered subcutaneously 2–3 times daily, with doses spaced at least 3 hours apart and ideally timed around sleep to capitalize on the natural nocturnal GH pulse. Fasting states may enhance the GH response.

Compounds That Pair Well

• CJC-1295 (without DAC) — A GHRH analogue that synergizes with GHRP-2 at the pituitary, producing greater GH release than either compound alone. This is the most common combination in research protocols.
• Ipamorelin — A more selective GH secretagogue that can be combined with GHRP-2 for enhanced GH stimulation with a more favorable side effect profile than higher-dose GHRP-2 alone.
• BPC-157 — A tissue-repair peptide that may complement the anabolic and recovery effects of GH axis stimulation.
• MK-677 (Ibutamoren) — An oral GH secretagogue that acts on the same receptor as GHRP-2 but with a much longer duration of action, providing sustained GH elevation.
• TB-500 — A thymosin beta-4 fragment that supports tissue repair and may complement the recovery-enhancing effects of elevated GH.